Cambridge Healthtech Institute’s Seventh Annual
Protein Aggregation and Stability in Biopharmaceuticals
Analytic, Formulation, Manufacturing and Regulatory Challenges
Part of the Tenth Annual PEGS: the essential protein engineering summit
May 8-9, 2014 | Seaport World Trade Center | Boston, Massachusetts
The study and prevention of protein aggregation and its consequences represents one of the most demanding tasks in biomedical research and pharmaceutical manufacturing today. Whether one’s interests lie in protein characterization or analytics, the study of protein aggregation-induced adverse effects or immunogenicity, or you work in formulation and process development for protein-based therapeutics, “Protein Aggregation and Stability in Biopharmaceutical Products” will provide a comprehensive real-world perspective on this challenging arena.
Protein Aggregation: Characterization to Support Clinical Development
Jamie Moore, Ph.D., Senior Scientist & Director, Early Stage Pharma Development, Genentech, Inc.
Strategy for Integrated Developability Assessment to Select Candidates for Clinical Development
Hubert Kettenberger, Ph.D., Principal Scientist, Roche Diagnostics GmbH
Methodologies to Assess Aggregation Propensities and Stability of Proteins in Biopharmaceutical Development
Malgorzata Tracka, Ph.D., Scientist II, Formulation Sciences, MedImmune
Mapping Aggregation Hotspots in mAbs with H/D Exchange Mass Spectrometry
David Weis, Ph.D., Assistant Professor, Chemistry, University of Kansas
An Accurate Analysis for the Determination of the Extent and Mechanism of Aggregation and the Stability of Proteins
Belinda Pastrana, Ph.D., Professor, Chemistry, University of Puerto Rico
Utilizing Biophysical Tools to Understand Protein Solution Behavior
Donna Luisi, Ph.D., Senior Principal Scientist, Biopharmaceutical R&D, Pfizer
Improving Aggregation Resistance of Single-Domain Antibodies by Increasing Their Net Negative Charge
Kendrick Turner, Ph.D., Postdoctoral Fellow, Center for Bio/Molecular Science and Engineering, U.S. Naval Research Laboratory
Engineering Antibodies to Mitigate Aggregation/Self-Association
Chris Lloyd, Ph.D., Scientist, Antibody Discovery & Protein Engineering, MedImmune Ltd.
Ultra-High Concentration Antibody Nanoparticle Dispersions are Reversible, Retain Bioactivity and are Not More Immunogenic
Jennifer Maynard, Ph.D., Assistant Professor, Chemical Engineering, University of Texas, Austin
Screening Methods to Study Aggregation of New Monoclonal Antibody Candidates in Human Plasma and Human Serum
Chakravarthy Narasimhan, Ph.D., Senior Principal Scientist, Bioprocess Development, Merck & Co.
Studies of the Aggregates Formed When Therapeutic Protein Solutions are Mixed with Human Plasma and Whole Blood: A New Research and Development Field
Tudor Arvinte, Ph.D., Professor, Biopharmaceutics, University of Geneva; CEO, Therapeomic, Inc.
Physiological Effects of Protein Aggregation
Vibha Jawa, Ph.D., Principal Scientist, Clinical Immunology, Amgen, Inc.
Aggregation of Human Recombinant Monoclonal Antibodies Enhances Their Presentation by Dendritic Cells In Vitro
Sebastian Spindeldreher, Ph.D., Head, Biologics Safety and Disposition, Novartis
Biological Impact of Aggregates: Immunogenicity, Biodistribution, In Vivo Response
Vasco Filipe, Ph.D., Research Scientist, ADOCIA